PRMT6 is required for initiating and amplifying macrophage-induced inflammation in heterotopic ossification by increasing CCL2 expression

Abstract

Heterotopic ossification (HO) is a debilitating disorder marked by ectopic bone formation in soft tissues, frequently triggered by inflammation after trauma. While macrophage-driven inflammation plays a critical role in HO pathogenesis, the molecular mechanisms governing its initiation, amplification and resolution remain elusive. Using a trauma/burn injury (TBI)-induced mouse model of HO, we identified rapid and sustained macrophage accumulation at the injury site during the early inflammatory phase, and macrophage depletion markedly suppressed HO formation. Transcriptomic profiling identified a pronounced upregulation of protein arginine methyltransferase 6 (PRMT6) in macrophages following injury. Genetic deletion or macrophage-targeted knockdown of Prmt6 reduced macrophage accumulation and significantly attenuated HO, without impairing tendon repair. Consistently, pharmacological inhibition of PRMT6 suppressed HO only when administered during the early inflammatory phase, indicating a restricted therapeutic window. Mechanistically, PRMT6 amplified macrophage chemotactic signaling by transcriptionally and epigenetically upregulating CCL2. Genetic disruption of macrophage-derived CCL2 phenocopied Prmt6 deficiency, whereas CCL2 supplementation rescued macrophage recruitment and partially restored HO in Prmt6-deficient mice. At the molecular level, PRMT6 formed a coactivation complex with NF-κB and catalyzed H3R17 asymmetric dimethylation at the Ccl2 promoter, thereby promoting sustained chemokine expression. Collectively, our findings identify PRMT6 as a central epigenetic amplifier of macrophage-driven inflammation that links early injury responses to ectopic bone formation. Targeting PRMT6 during the early inflammatory phase represents a promising strategy to prevent HO while preserving physiological tissue repair.

References

[1] Shehab D, Elgazzar AH, Collier BD. Heterotopic ossification. J. Nucl. Med.. 2002, 43: 346-353

[2] Shimono Ket al. . Potent inhibition of heterotopic ossification by nuclear retinoic acid receptor-γ agonists. Nat. Med.. 2011, 17: 454-460.

[3] Meyers Cet al. . Heterotopic ossification: a comprehensive review. JBMR. 2019, 3e10172

[4] Hoyt BW, Pavey GJ, Potter BK, Forsberg JA. Heterotopic ossification and lessons learned from fifteen years at war: a review of therapy, novel research, and future directions for military and civilian orthopaedic trauma. Bone. 2018, 109: 3-11.

[5] Vanden Bossche L, Vanderstraeten G. Heterotopic ossification: a review. J. Rehabil. Med.. 2005, 37: 129-136.

[6] Sorkin Met al. . Regulation of heterotopic ossification by monocytes in a mouse model of aberrant wound healing. Nat. Commun.. 2020, 11. 722

[7] Zhang Det al. . Targeting local lymphatics to ameliorate heterotopic ossification via FGFR3-BMPR1a pathway. Nat. Commun.. 2021, 12. 4391

[8] Medici D, Olsen BR. The role of endothelial-mesenchymal transition in heterotopic ossification. J. Bone Min. Res.. 2012, 27: 1619-1622.

[9] O’Brien EJ, Frank CB, Shrive NG, Hallgrímsson B, Hart DA. Heterotopic mineralization (ossification or calcification) in tendinopathy or following surgical tendon trauma. Int. J. Exp. Pathol.. 2012, 93: 319-331.

[10] Wozney JMet al. . Novel regulators of bone formation: molecular clones and activities. Science. 1988, 242: 1528-1534.

[11] Wiktor-Jedrzejczak Wet al. . Total absence of colony-stimulating factor 1 in the macrophage-deficient osteopetrotic (op/op) mouse. Proc. Natl. Acad. Sci. USA. 1990, 87: 4828-4832.

[12] Lobov IBet al. . WNT7b mediates macrophage-induced programmed cell death in patterning of the vasculature. Nature. 2005, 437: 417-421.

[13] Li Yet al. . The inflammation and reactive oxygen species regulated by Nrf2 and NF-κB signaling pathways in 630-nm light-emitting diode irradiation treated THP-1 monocytes/macrophages. Lasers Med. Sci.. 2021, 36: 1411-1419.

[14] Kan Cet al. . Inhibition of immune checkpoints prevents injury-induced heterotopic ossification. Bone Res.. 2019, 7: 33.

[15] Wang Xet al. . Inhibition of overactive TGF-β attenuates progression of heterotopic ossification in mice. Nat. Commun.. 2018, 9. 551

[16] Tu Bet al. . Macrophage-derived TGF-β and VEGF promote the progression of trauma-induced heterotopic ossification. Inflammation. 2023, 46202-216.

[17] Blanc RS, Richard S. Arginine methylation: the coming of age. Mol. Cell.. 2017, 65: 8-24.

[18] Gupta, S., Kadumuri, R. V., Singh, A. K., Chavali, S. & Dhayalan, A. Structure, activity and function of the protein arginine methyltransferase 6. Life11, 951 (2021).

[19] Cheng Det al. . Genetic evidence for partial redundancy between the arginine methyltransferases CARM1 and PRMT6. J. Biol. Chem.. 2020, 295: 17060-17070.

[20] Casadio Fet al. . H3R42me2a is a histone modification with positive transcriptional effects. Proc. Natl. Acad. Sci. USA. 2013, 110: 14894-14899.

[21] Guccione Eet al. . Methylation of histone H3R2 by PRMT6 and H3K4 by an MLL complex are mutually exclusive. Nature. 2007, 449: 933-937.

[22] Waldmann Tet al. . Methylation of H2AR29 is a novel repressive PRMT6 target. Epigenetics Chromatin. 2011, 4: 11.

[23] Zhang H, Han C, Li T, Li N, Cao X. The methyltransferase PRMT6 attenuates antiviral innate immunity by blocking TBK1-IRF3 signaling. Cell Mol. Immunol.. 2019, 16800-809.

[24] Luo Yet al. . Intestinal PPARα protects against colon carcinogenesis via regulation of methyltransferases DNMT1 and PRMT6. Gastroenterology. 2019, 157: 744-759.e744.

[25] Scaramuzzino Cet al. . Protein arginine methyltransferase 6 enhances polyglutamine-expanded androgen receptor function and toxicity in spinal and bulbar muscular atrophy. Neuron. 2015, 85: 88-100.

[26] Huang Tet al. . PRMT6 methylation of RCC1 regulates mitosis, tumorigenicity, and radiation response of glioblastoma stem cells. Mol. Cell.. 2021, 81: 1276-1291.e1279.

[27] Yea JHet al. . Tppp3(⁺) synovial/tendon sheath progenitor cells contribute to heterotopic bone after trauma. Bone Res.. 2023, 11: 39.

[28] Kang Het al. . The HIF-1alpha/PLOD2 axis integrates extracellular matrix organization and cell metabolism leading to aberrant musculoskeletal repair. Bone Res.. 2024, 1217.

[29] Kigerl KA, de Rivero Vaccari JP, Dietrich WD, Popovich PG, Keane RW. Pattern recognition receptors and central nervous system repair. Exp. Neurol.. 2014, 2585-16.

[30] Yu Met al. . HMGB1 signals through toll-like receptor (TLR) 4 and TLR2. Shock. 2006, 26: 174-179.

[31] Cherief Met al. . TrkA-mediated sensory innervation of injured mouse tendon supports tendon sheath progenitor cell expansion and tendon repair. Sci. Transl. Med.. 2023, 15. eade4619

[32] Fan Xet al. . Macrophage-Derived GSDMD plays an essential role in atherosclerosis and cross talk between macrophages via the mitochondria-STING-IRF3/NF-kappaB axis. Arterioscler Thromb. Vasc. Biol.. 2024, 44: 1365-1378.

[33] Zhao HYet al. . M2 macrophages, but not M1 macrophages, support megakaryopoiesis by upregulating PI3K-AKT pathway activity. Signal Transduct. Target Ther.. 2021, 6: 234.

[34] Raghu Het al. . CCL2/CCR2, but not CCL5/CCR5, mediates monocyte recruitment, inflammation and cartilage destruction in osteoarthritis. Ann. Rheum. Dis.. 2017, 76914-922.

[35] Huang Yet al. . Macrophages in heterotopic ossification: from mechanisms to therapy. NPJ Regen. Med.. 2021, 6: 70.

[36] Méndez-Ferrer Set al. . Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature. 2010, 466829-834.

[37] Ono Net al. . Vasculature-associated cells expressing nestin in developing bones encompass early cells in the osteoblast and endothelial lineage. Dev. Cell.. 2014, 29: 330-339.

[38] Kim JHet al. . The role of protein arginine methyltransferases in inflammatory responses. Mediators Inflamm.. 2016, 2016. 4028353

[39] Li Xet al. . Coordinated chemokine expression defines macrophage subsets across tissues. Nat. Immunol.. 2024, 25: 1110-1122.

[40] Liu SSet al. . The chemokine CCL1 triggers an AMFR-SPRY1 pathway that promotes differentiation of lung fibroblasts into myofibroblasts and drives pulmonary fibrosis. Immunity. 2021, 54: 2042-2056.e2048.

[41] Bajpai Get al. . Tissue Resident CCR2- and CCR2⁺ cardiac macrophages differentially orchestrate monocyte recruitment and fate specification following myocardial injury. Circ. Res.. 2019, 124: 263-278.

[42] Luther SA, Cyster JG. Chemokines as regulators of T cell differentiation. Nat. Immunol.. 2001, 2: 102-107.

[43] Neehus ALet al. . Human inherited CCR2 deficiency underlies progressive polycystic lung disease. Cell. 2024, 187: 390-408.e323.

[44] Winter Cet al. . Chrono-pharmacological targeting of the CCL2-CCR2 axis ameliorates atherosclerosis. Cell Metab.. 2018, 28: 175-182.e175.

[45] Kurihara T, Warr G, Loy J, Bravo R. Defects in macrophage recruitment and host defense in mice lacking the CCR2 chemokine receptor. J. Exp. Med.. 1997, 186: 1757-1762.

[46] Zhang Yet al. . Identification of biological pathways and genes associated with neurogenic heterotopic ossification by text mining. PeerJ. 2020, 8. e8276

[47] Leuschner Fet al. . Therapeutic siRNA silencing in inflammatory monocytes in mice. Nat. Biotechnol.. 2011, 29: 1005-1010.

[48] Fantuzzi L, Tagliamonte M, Gauzzi MC, Lopalco L. Dual CCR5/CCR2 targeting: opportunities for the cure of complex disorders. Cell Mol. Life Sci.. 2019, 76: 4869-4886.

[49] Frankel Aet al. . The novel human protein arginine N-methyltransferase PRMT6 is a nuclear enzyme displaying unique substrate specificity. J. Biol. Chem.. 2002, 277: 3537-3543.

[50] Peterson, J. R., et al. Direct mouse trauma/burn model of heterotopic ossification. J. Vis. Exp. 102, e52880 (2015).

[51] Bellver-Landete Vet al. . Microglia are an essential component of the neuroprotective scar that forms after spinal cord injury. Nat. Commun.. 2019, 10. 518

[52] Kong Eet al. . HSV-1 reactivation results in post-herpetic neuralgia by upregulating Prmt6 and inhibiting cGAS-STING. Brain. 2024, 147: 2552-2565.

Funding

National Natural Science Foundation of China (National Science Foundation of China)(81572201)

RIGHTS & PERMISSIONS

The Author(s)